Manejo terapéutico del carcinoma medular de tiroides metastásico: papel de los nuevos inhibidores de la tirosincinasa

García-Martín, Antonia; López-Ibarra Lozano, Pablo José; Triviño -Ibáñez, Eva María; Escobar-Jiménez, Fernando.
Endocrinol. nutr. (Ed. impr.) ; 60(3): 152-153, mar. 2013. ilus
Artículo en Español | IBECS (España) | ID: ibc-110919

Documentos relacionados

  1. Advances and controversies in the management of medullary thyroid carcinoma.
  2. RET TKI: potential role in thyroid cancers.
  3. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.
  4. [Endocrinology].
  5. A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis.
  6. [Efficacy and safety of vandetanib on advanced medullary thyroid carcinoma: single center result from a phase Ⅲ study].
  7. RAS proto-oncogene in medullary thyroid carcinoma.
  8. Vandetanib and the management of advanced medullary thyroid cancer.
  9. How does nintedanib overcome cancer drug-resistant mutation of RET protein-tyrosine kinase: insights from molecular dynamics simulations.
  10. Multikinase inhibitors in thyroid cancer.